Cargando…
Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review
Migraine is a complex and often debilitating neurological disease that affects more than 1 billion people worldwide. It is characterized by moderate-to-intense, throbbing headache attacks that are worsened by activity and is associated with nausea, vomiting, and sensitivity to light and sound. Migra...
Autores principales: | Rhyne, Christopher, Cohen, Joshua M., Seminerio, Michael J., Carr, Karen, Krasenbaum, Lynda J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256346/ https://www.ncbi.nlm.nih.gov/pubmed/37335663 http://dx.doi.org/10.1097/MD.0000000000033874 |
Ejemplares similares
-
Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
por: Nissan, George R., et al.
Publicado: (2022) -
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021) -
Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021) -
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020) -
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)